Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage Radiation + ADT +/- Abiraterone and Apalutamide in Prostate Cancer
NCT03141671Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2017
- Primary completion
- Apr 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of abiraterone and apalutamide in prostate cancer (PCa) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: PSA Progression Free Survival at 5 years. Started Nov 2017; status: active, not recruiting.
02
Drugs
abirateroneapalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03141671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03141671.